Although many cats with diabetes mellitus go into remission, the majority will require insulin again within a year. We are currently enrolling diabetic cats that have recently gone into remission in a study looking at a novel treatment to restore pancreatic β cell function. The drug used (Exenatide-ER, Bydureon®) is currently used in the management of Type 2 DM in people and has been extensively studied in cats. We expect that treated cats will have a sustained remission and remain euglycemic without the need for insulin injections.

Cats may be eligible for this study if they:
1. Have recently gone into diabetic remission (4-12 weeks since last insulin injection)
2. Have no evidence of severe concurrent disease
3. Are able to eat a high protein, low carbohydrate diet
4. Can be examined at the hospital once a month for 1 year

Cats will be randomly assigned to either the treatment group or the placebo group.

For more information about this study and other on-going clinical trials, please visit our website:
http://vetmed.tamu.edu/clinical-trials/internal-medicine